Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/55621
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer
Author: Rao, S.
Cunningham, D.
Price, T.
Hill, M.
Ross, P.
Tebbutt, N.
Norman, A.
Oates, J.
Shellito, P.
Citation: British Journal of Cancer, 2004; 91(5):839-843
Publisher: Nature Publishing Group
Issue Date: 2004
ISSN: 0007-0920
1532-1827
Statement of
Responsibility: 
S Rao, D Cunningham, T Price, M E Hill, P J Ross, N Tebbutt, A R Norman, J Oates and P Shellito
Abstract: This study was designed to assess the safety and efficacy of capecitabine and mitomycin C (MMC) in previously untreated patients with advanced colorectal cancer (CRC). Patients received capecitabine 2500 mg m2 day 1, orally divided in two doses of 1250 mg m-2 in the morning and evening for 14 days every 21 days and MMC 7 mg m-2 (maximum total dose 14 mg) as an intravenous bolus every 6 weeks for a total of four courses. The median age was 70 years (range 24–85) and the majority of patients (86.9%) were of performance status 1/2. The most common metastatic site was liver. In all, 84 patients were assessable for response. The overall response rate was 38% (95% CI: 27.7–49.3) and a further 33.3% of patients achieved stable disease over 12 weeks. There was good symptom resolution ranging from 64 to 86%. Grade 3/4 toxicity was as follows: hand–foot syndrome 19.7%; diarrhoea 10%; neutropenia 2.4%; infection 2.3%. Capecitabine and MMC have shown encouraging activity with a favourable toxicity profile, a convenient administration schedule, and could be considered for patients deemed unsuitable for oxaliplatin and irinotecan combinations.
Keywords: colorectal cancer; advanced; chemotherapy; capecitabine; mitomycin C
Rights: © 2004 Cancer Research UK
RMID: 0020092015
DOI: 10.1038/sj.bjc.6602039
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_55621.pdfPublished version101.56 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.